Vaginal Douching and Painting in Women Who Underwent Total Abdominal Hysterectomy

NCT ID: NCT03537313

Last Updated: 2020-10-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-15

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparison of the effectiveness of povidone-iodine douching and painting for reducing febrile morbidity after total abdominal hysterectomy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Total abdominal hysterectomy (TAH) is the most common gynecologic operation worldwide. The two most common complications after TAH are febrile and infectious morbidities, incidence varying between 5 and 50 percent. After performing TAH, vaginal canal must be breached and closed to be blind-pouch stump. Routing vaginal douching at the night before and on the morning of the surgical date, and intra-operative painting are routinely practiced. However, no good quality of evidence base supports the effectiveness of vaginal douching and painting in preventing febrile and infectious morbidities after TAH.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Febrile Morbidity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Factorial 2-by-2 open labeled randomised controlled trial
Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control-douching group

No preoperative vagina douching

Group Type NO_INTERVENTION

No interventions assigned to this group

Control-painting group

No intra-operative vagina painting

Group Type NO_INTERVENTION

No interventions assigned to this group

Vaginal douching group

Preoperative vaginal douches with povidone-iodine solution

Group Type EXPERIMENTAL

Vagina douching

Intervention Type PROCEDURE

Vaginal douches with 1000 ml of 1% povidone-iodine solution on the night before surgery and again on the morning of surgery

Vaginal painting group

Intra-operative vaginal painting with povidone-iodine solution

Group Type EXPERIMENTAL

Vagina painting

Intervention Type PROCEDURE

Vaginal painting of vagina stump after hysterectomy with 10% povidone-iodine solution 30 ml

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vagina douching

Vaginal douches with 1000 ml of 1% povidone-iodine solution on the night before surgery and again on the morning of surgery

Intervention Type PROCEDURE

Vagina painting

Vaginal painting of vagina stump after hysterectomy with 10% povidone-iodine solution 30 ml

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women who undergoing total abdominal hysterectomy
* Woman who agrees to participate in this study

Exclusion Criteria

* Women with history of sea-food or iodine allergy
* Women who undergo emergency TAH
* Women who have intestinal resection in this operation
* Women who have active pelvic inflammatory disease before operation
* Women who have fever before operation
* Women who received antibiotic within 1 weeks before operation
* Women who be immunocompromised host
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Department of Medical Services Ministry of Public Health of Thailand

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rajavithi hospital

Bangkok, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RJVAG001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.